Morgan Stanley maintains Recursion Pharmaceuticals at Equal-Weight, lowers price target to $5.60 from $5.90

Morgan Stanley kept Recursion Pharmaceuticals at Equal-Weight but reduced its price target to $5.60 from $5.90, a 5.1% cut. This implies a 105.9% upside from the Nov 17 close of $2.72.

Original reporting
Published Nov 18, 2026, 4:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 18, 2026, 4:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Morgan Stanley maintains Recursion Pharmaceuticals at Equal-Weight, lowers price target to $5.60 from $5.90 — source image
Decision brief

The 30-second read

$RXRXBearishLow
01

Why it matters

A lower target can influence short-term positioning and expectations, but unchanged rating suggests the analyst does not see a major deterioration requiring a downgrade.

02

Market read

Traders may use the target cut to reassess near-term valuation expectations, but it is unlikely to drive a major repricing without additional new fundamentals.

03

What to watch

Price-target changes can lag fundamentals; without new trial/regulatory information, traders may discount the note relative to broader biotech risk appetite.

Relevance 4/10Novelty 4/10Timing: as of the analyst note publication time, for same-day sentiment checks

Background

The article summarizes an analyst action from Morgan Stanley on Recursion Pharmaceuticals, including a maintained rating and a reduced price target.

Company-level read

Ticker impact

$RXRXBearishMedium confidence
Context

Morgan Stanley maintained Recursion Pharmaceuticals at Equal-Weight and cut its price target to $5.60 from $5.90, a 5.1% reduction.

Expected impact

Likely mild downward pressure or limited upside as traders adjust expectations to the reduced target, with muted follow-through given no rating change.

Evidence & confidence

This is a single-bank price-target cut without an upgrade or downgrade, so it is more sentiment-adjustment than a fundamental catalyst.

Market effects

Limited read-through to biotech/AI-drug discovery peers because it is a single-name target adjustment with no new clinical or regulatory data.

Minimal, as the catalyst is company-specific analyst commentary.

Low, no cross-market policy or macro linkage is described.

Counterpoint

Because the rating stays Equal-Weight, the market may treat the target cut as incremental and focus on upcoming company-specific catalysts (trials, approvals, partnerships).

Key entities

  • Recursion Pharmaceuticals

    Subject of the analyst note, rated Equal-Weight with a lowered price target.

  • Morgan Stanley

    Maintained the rating and reduced the price target.

Related articles

$RXRXMed

Recursion Aligns With FDA On Phase 3 Trial Design For FAP Drug REC-4881; Stock Up

Recursion Pharmaceuticals (RXRX) aligned with the FDA on the Phase 3 trial design for REC-4881, an oral MEK1/2 inhibitor for familial adenomatous polyposis (FAP). The trial, expected to start in late 2027, will assess composite event-free survival as the primary endpoint. REC-4881 has shown a 47% median reduction in total polyp burden in Phase 1b/2 trials. RXRX shares were up 4.41% in premarket trading.

$RXRXMedAI 8/10

Recursion (RXRX) Q3 2026 Earnings Call Transcript

Recursion (RXRX) reported Q3 2026 earnings, highlighting clinical data for REC-4881 and REC-1245. REC-4881 showed significant reductions in polyp burden and safety. REC-1245 demonstrated early activity in solid tumors. The company secured $535M in partner cash inflows and extended cash runway to 2029. Operating expenses for 2026 were lowered to $375M, with 2027 expected under $360M. Sanofi and Roche collaborations advanced, with milestones and royalties. Fred Hassan was appointed board chair.

$RXRXMedAI 8/10

What Recursion Pharmaceuticals (RXRX) Said on Its Q3 Earnings Call

Recursion Pharmaceuticals (RXRX) reported Q3 updates, including 55% and 50% median reductions in upper and lower GI polyp burdens, respectively. REC-1245 showed partial responses in advanced solid tumors. Sanofi exercised an option, triggering a $10M payment. RXRX raised $200M in financing, extending cash runway into 2029. The company expects to start a registrational study in 2H 2027.

$RXRXHighAI 8/10

Recursion's Q3 Earnings Beat Estimates on Sanofi Milestone Revenues

Recursion Pharmaceuticals reported a narrower-than-expected Q3 2026 loss of 22 cents per share, with revenues of $18.55 million, up 258.5% YoY, driven by a $10 million Sanofi milestone payment. Operating expenses declined, and the company advanced its pipeline, including REC-4881 and REC-1245. RXRX shares are down 6.4% YTD.